证券代码：301103 证券简称：何氏眼科 公告编号：2025-044 公司董事会对封江涛先生在公司首次公开发行股票并在创业板上市项目及 持续督导期间所做的工作表示衷心的感谢！ 特此公告。 辽宁何氏眼科医院集团股份有限公司董事会 2025 年 10 月 23 日 1 附件：保荐代表人铁维铭的简历 辽宁何氏眼科医院集团股份有限公司 关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）于近日收到中原证 券股份有限公司（以下简称"中原证券"）出具的《关于更换辽宁何氏眼科医院集 团股份有限公司持续督导保荐代表人的函》。现将具体情况公告如下： 中原证券作为公司首次公开发行股票并在创业板上市的保荐机构，原委派的 保荐代表人为封江涛先生和钟坚刚先生，现因封江涛先生工作变动不再继续担任 上述项目持续督导期间的保荐代表人，中原证券决定委派保荐代表人铁维铭先生 接替封江涛先生担任贵公司持续督导期间的保荐代表人，继续履行持续督导职责。 本次变更不影响中原证券对公司的持续督导工作。本次保荐代表人变更后， ...

证券代码：301103 证券简称：何氏眼科 公告编号：2025-043 辽宁何氏眼科医院集团股份有限公司 关于持股 5%以上股东减持计划实施完成的公告 公司持股 5%以上股东先进制造产业投资基金（有限合伙）保证向本公司提供 的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"或"何氏眼科"）于 2025 年 7 月 1 日披露了《关于持股 5%以上股东减持股份预披露公告》（公告编 号：2025-021），股东先进制造产业投资基金（有限合伙）（以下简称"先进制造 基金"）计划在本公告披露之日起十五个交易日后的三个月内（即 2025 年 7 月 22 日至 2025 年 10 月 21 日期间），通过证券交易所集中竞价和大宗交易方式减 持公司股份合计不超过 3,106,074 股（占公司剔除回购专用证券账户中股份数量 后的总股本比例的 2%）。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 近日，公司收到上述股东出具的《关于股份减持计划期限届满暨实施情况告 知函 ...

一、募集资金的基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意辽宁何氏 眼科医院集团股份有限公司首次公开发行股票注册的批复》（证监许可【2022】 126 号）同意注册，辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）首 次公开发行人民币普通股（A 股）3,050 万股，每股面值 1 元，每股发行价格为 人民币 42.5 元，募集资金总额为人民币 129,625.00 万元，扣除与本次发行有关 的费用后募集资金净额为人民币 116,431.13 万元。募集资金已划至公司指定账户。 上述募集资金到位情况经容诚会计师事务所（特殊普通合伙）于 2022 年 3 月 16 日出具的"容诚验字[2022]110Z0006 号"《验资报告》验证。公司已将上述 募集资金全部存放于募集资金专户管理，并与保荐机构、存放募集资金的商业银 行签署募集资金三方监管协议。详细情况请参见公司已于 2022 年 4 月 2 日披露 于巨潮资讯网（http://www.cninfo.com.cn）的《关于签署募集资金三方监管协议 的公告》。 证券代码：301103 证券简称：何氏眼科 公告编号：2025-042 辽 ...

证券代码：301103 证券简称：何氏眼科 公告编号：2025-041 辽宁何氏眼科医院集团股份有限公司 2025 年第二次临时股东会决议公告 2.会议召开日期和时间： 现场会议时间为：2025 年 10 月 20 日（星期一）14:00 网络投票时间为：2025 年 10 月 20 日（星期一） 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1.本次股东会无增加、变更、否决提案的情况。 2.本次股东会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）2025 年第二次临 时股东会于 2025 年 10 月 20 日召开，公司董事会已于 2025 年 9 月 23 日在巨潮 资讯网上刊登了《关于召开 2025 年第二次临时股东会的通知》。 本次股东会由公司董事会召集，现场会议由公司董事长何伟先生主持，会议 召开符合《公司法》《上市公司股东会规则》《深圳证券交易所创业板股票上市规 则》及《公司章程》等规定。 1.会议召开方式：本次股东会采用现场和网络投票相结合的方式召开。 其中，通过深圳 ...

北京市中伦律师事务所 关于辽宁何氏眼科医院集团股份有限公司 2025 年第二次临时股东会的 法律意见书 二〇二五年十月 致：辽宁何氏眼科医院集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受辽宁何氏眼科医院集团股 份有限公司（以下简称"公司"）委托，指派本所律师对公司 2025 年第二次临时 股东会（以下简称"本次股东会"）的合法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）《上市公司股东会规则》 （以下简称"《股东会规则》"）等现行有效的法律、法规和规范性文件以及《辽 宁何氏眼科医院集团股份有限公司章程》（以下简称"《公司章程》"）的规定 而出具。 为出具本法律意见书，本所律师审查了公司本次股东会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必 需的材料，所提供的原始材料、副本、复印件等材料、口头证言均符合真实、准 确、完整的要求，有关副本、复印件材料与正本原始材料一致。 在本法律意见书中，本所律师仅对本次股东会的召集、召开程序、出席会议 人员的资格、召集 ...

Core Viewpoint - The company is actively involved in stem cell technology and regenerative medicine, with recent developments indicating a focus on corneal and retinal stem cell research, as well as a strategic acquisition to enhance its capabilities in this field [2]. Group 1: Company Performance - As of October 15, 2025, the company's stock price closed at 20.85 yuan, reflecting a 2.16% increase, with a trading volume of 17,200 shares and a turnover of 35.56 million yuan [1]. - The company reported a profit of over 40 million yuan in its mid-year report, a significant increase from 16 million yuan in the previous year's third-quarter report [2]. Group 2: Strategic Initiatives - The company has acquired Japan's Medical Path Co., Ltd., which specializes in regenerative medicine, focusing on drug research, development, and commercialization, particularly in the use of stem cells and exosomes [2]. - The company is collaborating with genetic testing firms to conduct pathogenic and susceptibility gene testing for complex eye diseases, indicating a commitment to precision medicine [2]. Group 3: Market Activity - On October 15, 2025, there was a net inflow of 2.81 million yuan from major funds, suggesting active market interest [2]. - Retail investors showed a net outflow of 1.50 million yuan, while speculative funds experienced a net outflow of 1.31 million yuan, indicating mixed investor sentiment [2].

Core Insights - The 43rd European Society of Cataract and Refractive Surgeons annual meeting was held in Copenhagen, Denmark, where Professor Li Jun from Shenyang He Eye Hospital presented research on the correlation between different refractive groups and the vertical ciliary sulcus diameter [1] - The study revealed a significant nonlinear relationship between the horizontal and vertical ciliary sulcus diameter (STS) and refractive power, with distinct morphological differences in ciliary sulcus among various refractive groups [1] - Higher degrees of myopia (greater equivalent spherical power SE) corresponded to more pronounced differences between vertical and horizontal ciliary sulcus diameters, indicating a breakthrough for ICL surgery [1] Company and Industry Summary - The research provides quantitative anatomical references for personalized ICL size selection, surgical planning, and complication prevention, potentially leading to the development of new ICL calculation formulas [1] - This advancement aims to significantly reduce the incidence of secondary surgeries required for ICL lens replacement due to unexpected vault heights, showcasing the research strength and clinical leadership of He Eye Hospital in the field of refractive surgery [1] - He Eye Hospital plans to focus on the strategic goal of building the "He Smart City of Light," leveraging technological innovation and the advantages of a comprehensive eye health ecosystem to enhance eye care research and international collaboration [1]

Core Viewpoint - He Eye Hospital (301103) is actively engaged in stem cell research and has acquired a Japanese company specializing in regenerative medicine, indicating a strategic focus on advancing its capabilities in this field [1] Group 1: Stem Cell Technology - The company acknowledges the importance of stem cell technology in clinical medicine and its role in precision medicine, particularly in ophthalmology [1] - Significant research has been conducted in areas such as corneal and retinal stem cells, highlighting the company's commitment to advancing this field [1] Group 2: Collaboration and Acquisitions - The company collaborates with genetic testing firms to conduct pathogenic and susceptibility gene testing for complex eye diseases, enhancing diagnostic and treatment capabilities [1] - The acquisition of Japan's Medical Pathway Co., Ltd. focuses on research and application in regenerative medicine, covering drug research, development, and commercialization [1] Group 3: Business Impact - The recent acquisition is not expected to have a significant impact on the company's current main business operations or performance [1] - The company commits to timely disclosures regarding any major developments in line with regulatory requirements [1]

Core Insights - The 43rd European Society of Cataract and Refractive Surgeons (ESCRS2025) conference was held in Copenhagen, Denmark, where Professor Li Jun from Shenyang He Eye Hospital presented groundbreaking research on the correlation between different refractive groups and the vertical ciliary sulcus diameter [1][2] - The study revealed a significant nonlinear relationship between the horizontal and vertical ciliary sulcus diameter (STS) and refractive power, with distinct morphological differences in ciliary sulcus among various refractive groups [1] - Higher degrees of myopia (greater equivalent spherical power SE) correspond to more pronounced differences between vertical and horizontal ciliary sulcus diameters, which is critical for ICL (Implantable Collamer Lens) surgery [1] Company and Industry Summary - The research provides quantitative anatomical references for personalized ICL size selection, surgical planning, and complication prevention, potentially leading to the development of new ICL calculation formulas [2] - This advancement is expected to significantly reduce the incidence of secondary surgeries required due to mismatched vault heights, highlighting the research strength and clinical leadership of He Eye Hospital in the field of refractive surgery [2]

Core Viewpoint - The company has announced the public disclosure of the list of incentive objects for the 2025 Restricted Stock Incentive Plan, confirming compliance with relevant regulations and the absence of objections during the public notice period [1][2][4][8]. Group 1: Public Disclosure of Incentive Plan - The company held a board meeting on September 19, 2025, to approve the draft of the 2025 Restricted Stock Incentive Plan [1][10]. - The public notice period for the incentive objects was from September 30, 2025, to October 14, 2025 [3]. - The public notice was conducted internally, allowing employees to provide feedback through various channels, with no objections received [4][5]. Group 2: Verification of Incentive Objects - The board's remuneration and assessment committee verified the list of incentive objects against their qualifications, ensuring compliance with the management regulations and listing rules [5][6]. - The incentive objects include core management personnel and key staff, excluding directors, senior management, and significant shareholders [7][8]. - The committee confirmed that the basic information of the incentive objects is accurate and meets the conditions set forth in the management regulations [7][8]. Group 3: Insider Information Compliance - The company conducted a self-inspection regarding insider trading by individuals with knowledge of the incentive plan, confirming no trading activities occurred during the specified period [10][11]. - All insider information handlers were registered, and confidentiality measures were implemented to prevent information leakage [12]. - The self-inspection concluded that there were no violations of insider trading regulations related to the incentive plan [12].